In Plain English: Update on Melanoma Vaccines, 2024
By Kim Margolin, M.D., FACP, FASCO Recap and background on tumor vaccines We last visited the topic of vaccines in…
Melanoma Research
10/17/2024
In Plain English: Update on Melanoma Vaccines, 2024
By Kim Margolin, M.D., FACP, FASCO Recap and background on tumor vaccines We last visited the topic of vaccines in…
|
|
09/20/2024
Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin
How much is enough? Exploring excisional margins for in situ melanoma When a patient with melanoma in situ has a…
|
09/15/2024
Long-term Results Continue to Show a Benefit with Nivolumab and Ipilimumab
There is good news for patients with melanoma who received immunotherapy. Survival results from a major clinical trial, CheckMate-067, show…
|
09/15/2024
Ten Years of Pembrolizumab Shows Sustained Results
There is good news for patients with advanced melanoma who received pembrolizumab. Results from a clinical trial after ten years…
|
09/15/2024
Oncolytic Virotherapy Shows Promise in Advanced Melanoma that Failed Immunotherapy
New clinical trial data shows that additional options may soon become available for patients with melanoma for whom immunotherapy did…
|
09/15/2024
New Therapies Under Investigation for Patients With Metastatic Uveal Melanoma
Results from a Phase 2 clinical trial for patients with advanced uveal melanoma were presented at ESMO 2024 on September…
|
09/14/2024
News from ESMO: NADINA Trial Update in Stage III Melanoma
A follow-up report with data from NADINA was presented at the European Society for Medical Oncology (ESMO) Congress on September…
|
08/26/2024
New Specialty Manages Skin Concerns and Keeps Patients on Therapy
Cancer treatment—including and especially melanoma—unfortunately, produces a risk of side effects impacting the feeling and vitality of the skin. Changes…
|
07/18/2024
Everything Coming up Rosy is not a Health Tune
People with the chronic inflammatory skin condition rosacea shouldn’t skip out on check-ups. According to a new research study from…
|
07/02/2024
Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
By Mandi Murph Treatment may be changing for patients with Stage III melanoma. Recent clinical trial results show improved outcomes…
|
Recent Posts
Dec. 12, 2024
Navigating Melanoma Together: 2024 Podcast Wrap-Up
Dec. 10, 2024
Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel
Dec. 09, 2024
Managing Melanoma During the Holiday Season
Dec. 05, 2024
Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship
Dec. 03, 2024